Format

Send to

Choose Destination
AIDS Res Hum Retroviruses. 2017 Apr;33(4):395-403. doi: 10.1089/AID.2016.0073. Epub 2016 Dec 16.

Analytical Advances in the Ex Vivo Challenge Efficacy Assay.

Author information

1
1 Alpha StatConsult, LLC , Damascus, Maryland.
2
2 School of Mathematical Sciences, Rochester Institute of Technology , Rochester, New York.
3
3 Department of Medicine, David Geffen School of Medicine at UCLA, Center for HIV Prevention Research, UCLA AIDS Institute , Los Angeles, California.
4
4 School of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania.
5
5 Magee Womens Research Institute , Pittsburgh, Pennsylvania.
6
6 CONRAD, Eastern Virginia Medical School , Norfolk and Arlington, Virginia.
7
7 Division of Infectious Diseases, Faculty of Medicine, Imperial College , London, United Kingdom .
8
8 Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Southern California , Los Angeles, California.
9
9 Guys and St. Thomas' NHS Foundation Trust , London, United Kingdom .
10
10 Advanced Bioscience Laboratories , Gaithersburg, Maryland.

Abstract

The ex vivo challenge assay is being increasingly used as an efficacy endpoint during early human clinical trials of HIV prevention treatments. There is no standard methodology for the ex vivo challenge assay, although the use of different data collection methods and analytical parameters may impact results and reduce the comparability of findings between trials. In this analysis, we describe the impact of data imputation methods, kit type, testing schedule and tissue type on variability, statistical power, and ex vivo HIV growth kinetics. Data were p24 antigen (pg/ml) measurements collected from clinical trials of candidate microbicides where rectal (n = 502), cervical (n = 88), and vaginal (n = 110) tissues were challenged with HIV-1BaL ex vivo. Imputation of missing data using a nonlinear mixed effect model was found to provide an improved fit compared to imputation using half the limit of detection. The rectal virus growth period was found to be earlier and of a relatively shorter duration than the growth period for cervical and vaginal tissue types. On average, only four rectal tissue challenge assays in each treatment and control group would be needed to find a one log difference in p24 to be significant (alpha = 0.05), but a larger sample size was predicted to be needed for either cervical (n = 21) or vaginal (n = 10) tissue comparisons. Overall, the results indicated that improvements could be made in the design and analysis of the ex vivo challenge assay to provide a more standardized and powerful assay to compare efficacy of microbicide products.

KEYWORDS:

HIV; HIV prevention; bioinformatics; drug discovery

PMID:
27841671
PMCID:
PMC5372762
DOI:
10.1089/AID.2016.0073
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center